Lesson plan

Simufilam

Simufilam (PTI-125) is an experimental medication for the treatment of Alzheimer's disease that was being developed by the American pharmaceutical firm Cassava Sciences. Its development was discontinued in November 2024 after it failed to show clinical benefit during phase III clinical trials.

Back to article

Article summary

Simufilam (PTI-125) is an experimental medication for the treatment of Alzheimer's disease that was being developed by the American pharmaceutical firm Cassava Sciences. Its development was discontinued in November 2024 after it failed to show clinical benefit during phase III clinical trials.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.